Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.5    
    

 
 

EXCHANGE AND SHAREHOLDERS AGREEMENT    
    

        THIS EXCHANGE AND SHAREHOLDERS AGREEMENT (this "Agreement") is made as of February 6, 2004, among JSG
Packaging Limited, a private limited company organized under the laws of the Republic of Ireland with company number 380620 (the "Company"), the MDCP
Co-Investors and each of the Persons listed on the Schedule of Additional Investors attached hereto (each an "Additional Investor" and
collectively, the "Additional Investors"). The MDCP Co-Investors and the Additional Investors are collectively referred to herein as the
"Investors" and in the singular as an "Investor". Except as otherwise indicated herein, capitalized
terms used herein are defined in Section 10 hereof. 

        The
Company and each Investor desire to enter into an agreement pursuant to which such Executive shall exchange, and the Company shall issue, one of the Company's Ordinary Shares,
nominal value €0.001 per share (the "Ordinary Shares") in exchange for each Ordinary Share held by the Investor in Jefferson Smurfit
Group Limited (formerly MDCP Acquisitions Limited). The exchange and issuance referred to in the immediately foregoing sentence is being consummated in connection with the exchange of each issued and
outstanding Ordinary Share, Class A Convertible Share, Class B Convertible Share and Class C Convertible Share of Jefferson Smurfit Group Limited for one Ordinary Share,
Class A Convertible Share, Class B Convertible Share and Class C Convertible Share of the Company, respectively (including as may result from any compulsory share acquisition
under Section 204 of the Irish Companies Act, such transaction, the "Exchange"). 

        The
Company and the Investors are also entering into this Agreement in order to record the arrangements which they have agreed should apply to the Investors' participation in the Company
and to set out certain terms governing the relationship amongst the Investors as shareholders. 

        NOW,
THEREFORE, the parties hereto agree as follows: 

        Section 1.    Exchange.    

        1A.    Exchange for Ordinary Shares.    On the date hereof or any other date agreed to by the Company and an Investor
(for each such Investor, such Investor's "Exchange Date"), each Investor (other than the MDCP Co-Investors) shall deliver to the Company all
of the Ordinary Shares of Jefferson Smurfit Group Limited (formerly MDCP Acquisitions Limited) owned by such Investor (each such share, a "JSG Share"),
as set forth opposite such Investor's name on the Schedule of Investors attached hereto, and in exchange therefor, the Company shall deliver to each
such Investor one Ordinary Share of the Company for each JSG Share so delivered. 

        1B.    Mechanics.    The closing of the exchange of the JSG Shares for the shall take place at the offices of the
Company at Beech Hill, Clonskeagh, Dublin, Ireland. On the Exchange Date for any Investor, the following transactions shall occur in the following order: 

        (i)    each
Investor deliver all JSG Shares owned by such Investor (as set forth opposite such Investor's name on the Schedule of
Investors attached hereto, free and clear of all liens, encumbrances, security interests or other restrictions on transfer, together with share transfer forms in respect of all
such JSG Shares for which, together with the relevant share certificates or indemnities in lieu thereof; and 

        (ii)   the
Company, acting through its board of directors, shall issue to such Investor acquiring Ordinary Shares hereunder the number of Ordinary Shares set forth opposite
such Investor's name on the Schedule of Investors attached hereto; and 

        (iii)  the
name of such Investor (or its nominee) shall then be entered into the Company's register of members as the holder of the number of Ordinary Shares for which the
exchange was consummated hereunder and such Investor (or its nominee) shall be issued a share 

certificate
by the Company evidencing those Ordinary Shares upon filing of the appropriate documentation in the Companies Registration Office in Dublin; and 

        (iv)  the
Registration Agreement shall have been amended and restated in substantially the form attached hereto as  Exhibit A and such Investor shall deliver an executed counterpart thereto to the Company;
and 

        (v)   the
Corporate Governance Agreement shall have been amended and restated in substantially the form attached hereto as  Exhibit B and such Investor shall have delivered an executed counterpart thereto to
the Company. 

        Section 2.    [Intentionally
Omitted] 

        Section 3.    Covenants of the Company.    

        3A.    Financial Statements and Other Information.    Until the earlier of the effective date of the Company's initial
Listing or the date of consummation of a Sale of the Company, the Company shall deliver to each Investor and to each other holder of at least 15% of the Ordinary Shares. 

        (i)    as
soon as available but in any event within 30 days after the end of each monthly accounting period in each fiscal year, unaudited consolidated statements of
income and cash flows of the Company and its Subsidiaries for such monthly period and for the period from the beginning of the fiscal year to the end of such month, and a consolidated balance sheet of
the Company and its Subsidiaries as of the end of such monthly period; 

        (ii)   as
soon as available but in any event within 45 days after the end of each quarterly accounting period in each fiscal year, unaudited consolidated statements of
income and cash flows of the Company and its Subsidiaries for such quarterly period and for the period from the beginning of the fiscal year to the end of such quarter, and a consolidated balance
sheet of the Company and its Subsidiaries as of the end of such quarterly period, setting forth in each case comparisons to the annual budget and to the corresponding period in the preceding fiscal
year; 

        (iii)  within
120 days after the end of each fiscal year, consolidating and consolidated statements of income and cash flows of the Company and its Subsidiaries for
such fiscal year, and consolidating and consolidated balance sheets of the Company and its Subsidiaries as of the end of such fiscal year, setting forth in each case comparisons to the annual budget
and to the preceding fiscal year, accompanied with respect to the consolidated portions of such statements (except with respect to budget data), by an opinion of an independent accounting firm of
recognized international standing acceptable to the Board; and 

        (iv)  at
least 30 days after the beginning of each fiscal year, an annual budget prepared on a monthly basis for the Company and its Subsidiaries for such fiscal year
(displaying anticipated statements of income and cash flows), and promptly upon preparation thereof any other significant budgets prepared by the Company and any revisions of such annual or other
budgets. 

        3B.    Inspection of Property.    Until the earlier of the effective date of the Company's initial Listing or the date
of the consummation of a Sale of the Company, the Company shall permit any representatives designated by any Investor or any holder of at least 15% of the outstanding Ordinary Shares, upon reasonable
notice and during normal business hours and such other times as any such holder may reasonably request, to (i) visit and inspect any of the properties of the Company and its Subsidiaries,
(ii) examine the corporate and financial records of the Company and its Subsidiaries and make copies thereof or extracts therefrom and (iii) discuss the affairs, finances and accounts of
any such corporations with the directors, chief executive officer and chief financial officer of the Company. 

        3C.    Preemptive Right.    

        (i)    If
the Company proposes to issue any additional Ordinary Shares or Equity Securities or Equity Equivalents that are convertible or exercisable into Ordinary Shares to
the MDCP Co-Investors or any of their respective Affiliates (the "New Shares") after the date hereof, each Investor shall have the right to
purchase all or part of a portion of the New Shares equal to the product of (a) the total number of New Shares proposed to be issued, multiplied
by (b) a fraction, (I) the numerator of which is the number of Class D Convertible Shares (if any) and Ordinary Shares held by such shareholder as of the
date hereof and (II) the denominator of which is the total number of Class D Convertible Shares and Ordinary Shares which are held by all shareholders immediately prior to the proposed
issuance. 

        (ii)   The
Company shall give each Investor written notice of any proposed issuance of New Shares (the "Option Issuance
Notice") describing the price and terms upon which the Company proposes to issue and sell such New Shares. During the 20-day period following the date of delivery
of the Option Issuance Notice (the "Election Period") each Investor may exercise his, her or its right to purchase New Shares in accordance with this
paragraph 3C, for the price and upon the terms and conditions specified in the Option Issuance Notice by giving written notice to the Company and stating therein the quantity of New Shares to
be purchased. 

        (iii)  In
the event that any Investor fails to exercise its right to subscribe for any New Shares which it is entitled to subscribe for under this paragraph 3C, the
Company shall have 90 days following the Election Period to issue or enter into an agreement to issue the New Shares not elected to be subscribed for by the other Investors at the price and
upon terms not substantially more favorable to the prospective subscribers for such New Shares than those specified in the Option Issuance Notice. In the event the Company has not issued the New
Shares or entered into an agreement to issue the New Shares within the said 90-day period, the Company shall not thereafter issue otherwise transfer such New Shares without first offering
such New Shares to the Investors in the manner provided in this paragraph 3C. 

        (iv)  If
an Investor elects to subscribe for any New Shares pursuant to this paragraph 3C the closing of such subscription shall occur at such time and at such
location selected by the Company. 

        (v)   Notwithstanding
anything else to the contrary set forth herein, the provisions of this paragraph 3C shall not apply to (A) any Excluded Issuances or
(B) as long as such issuance is made on the basis of Ordinary Share or Convertible Share of Jefferson Smurfit Group Limited for one Ordinary Share or Convertible Share, as the case may be, of
the Company, any issuance in connection with the Exchange. 

        Section 4.    Representations and Warranties of the Company.    As a material inducement to the Investors to
enter into this Agreement and subscribe for the Ordinary Shares, the Company hereby represents and warrants to the Investors, as of the date of this Agreement, that: 

        4A.    Organization and Corporate Power.    The Company is a public limited company duly organized and validly
existing under the laws of Ireland and is qualified to do business in every jurisdiction in which the failure to so qualify might reasonably be expected to have a material adverse effect on the
financial condition, operating results, assets, operations or business prospects of the Company and its Subsidiaries taken as a whole. The Company has all requisite corporate power and authority and
all material licenses, permits and authorizations necessary to own and operate its properties, to carry on its businesses as now conducted and presently proposed to be conducted and to carry out the
transactions contemplated by this Agreement. The copies of the Company's Articles of Association which have been furnished to the Investors' counsel reflect all amendments made thereto at any time
prior to the date of this Agreement and are correct and complete. 

        4B.    Authorised Share Capital and Related Matters.    

        (i)    The
authorized share capital of the Company is as set forth in the Company's Articles of Association. As of the Exchange Date, all of the outstanding Ordinary Shares are
validly issued and fully paid. 

        (ii)   There
are no statutory or contractual shareholders preemptive rights or rights of refusal with respect to the issuance of the Ordinary Shares hereunder, except as may
be provided herein and in the MIP, the MEIAs or the Articles of Association. There are no agreements between the Company's shareholders with respect to the voting or transfer of the Company's share
capital or with respect to any other aspect of the Company's affairs, except for this Agreement and the MIP, the MEIA, the Corporate Governance Agreement and the Registration Agreement. 

        (iii)  The
Ordinary Shares being issued to an Additional Investor hereunder are being issued to such Additional Investor free and clear of all liens, encumbrances and
restrictions (other than restrictions existing under applicable securities laws or created hereunder or by the agreements contemplated hereby) and the issuance of the Ordinary Shares hereunder has
been duly authorized by the Company. 

        4C.    Authorization; No Breach.    The execution, delivery and performance of this Agreement has been duly authorized
by the Company. This Agreement constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i) as such enforcement is limited
by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors' rights generally and (ii) for limitations imposed by general principles of equity. The execution,
delivery and performance by the Company of this Agreement do not and will not (i) conflict with or result in a breach of the terms, conditions or provisions of, (ii) constitute a default
under, (iii) result in the creation of any lien, security interest, charge or encumbrance upon the Company's share capital or assets pursuant to, (iv) give any third party the right to
modify, terminate or accelerate any obligation under, (v) result in a violation of, or (vi) require any authorization, consent, approval, exemption or other action by or notice to any
court or administrative or governmental body pursuant to, the Articles of Association of the Company, or any law, statute, rule or regulation to which the Company is subject, or any agreement,
instrument, order, judgment or decree to which the Company is a party or by which it is bound. 

        4D.    Compliance with Laws.    The Company has not violated any law or any governmental regulation or requirement
which violation would reasonably be expected to have a material adverse effect upon its business, financial condition, operating results, assets, liabilities, customer, employee or supplier relations,
prospects or value. The Company is not subject to any clean up liability under any applicable environmental law, rule or regulation. 

        Section 5.    Investors' Representations.    Each of the Investors hereby represents and warrants to each other
Investor and to the Company for itself, severally and ratably and not jointly, as of the Exchange Date, that: 

        5A.    Corporate Existence and Power.    If such Investor is a company or a partnership, such Investor is duly
organized and validly existing under the laws of its jurisdiction of organization and has all corporate, partnership or limited liability company powers (as applicable) and all material governmental
and regulatory licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted. If such Investor is a company or a partnership, such Investor is duly
qualified to do business in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified would not have a material adverse effect on such
Investor. 

        5B.    Authorization.    If such Investor is a company or a partnership, the execution, delivery and performance by
such Investor of this Agreement and the other agreements and documents contemplated hereby to which such Investor is a party and the consummation of the transactions 

contemplated
hereby and thereby are within such Investor's corporate, partnership or limited liability company powers (as applicable) and have been duly authorized by all necessary corporate,
partnership or limited liability company action (as applicable) on the part of such Investor. Each Investor that is an individual has sufficient legal capacity to assess, execute and deliver this
Agreement on his or her own behalf. This Agreement and each other agreement and document contemplated hereby to which the Investor is or becomes a party constitutes a legal, valid and binding
agreement of such Investor, enforceable against such Investor in accordance with its terms, except (i) as such enforcement is limited by bankruptcy, insolvency and other similar laws affecting
the enforcement of creditors' rights generally and (ii) for limitations imposed by general principles of equity. 

        5C.    Governmental Authorization.    The execution, delivery and performance by such Investor of this Agreement and
the consummation of the transactions contemplated hereby and thereby require no action with respect to such Investor by or in respect of, or filing with, any governmental or regulatory entity other
than (i) compliance with any applicable filing requirements with competition authorities (each of which has been made by such Investor) and (ii) other filings, notifications and consents
that may be required after consummation of the transactions contemplated hereby or are immaterial to the consummation of the transactions contemplated hereby. 

        5D.    Noncontravention.    The execution, delivery and performance by such Investor of this Agreement and the
consummation of the transactions contemplated hereby and thereby do not and will not (i) violate the organizational documents, if any, of such Investor, (ii) violate any applicable law,
except for any such violation which would not have a material adverse effect on the ability of such Investor to consummate the transactions and perform all of such Investor's obligations hereunder
contemplated hereby and thereby or (iii) require any consent or other action by any Person, or constitute a default, under any provision of any agreement or other instrument binding upon such
Investor, except as to matters which would not be material to such Investor. 

        5E.    Ownership of JSG Shares.    The JSG Shares set forth opposite such Investor's name on the  Schedule of Investors attached
hereto and being exchanged by such Investor hereunder are owned beneficially and of record by such Investor free and
clear of all liens, encumbrances, security interests and other restrictions on transfer. 

        Section 6.    Additional Investor Representation and Warranty,    Each Additional Investor represents, warrants
and covenants to the MDCP Co-Investors and the Company that: (a) the determination of such Additional Investor to acquire the Ordinary Shares pursuant to this Agreement and to enter
into the agreements contemplated hereby has been made by such Additional Investor on the basis of its own due diligence investigation, independent of any other Investor and independent of any
statements or opinions as to the advisability of such purchase or as to the properties, business, prospects or condition (financial or otherwise) of the Company, the Group or any of their respective
Subsidiaries which may have been made or given by any other Investor or by any agent or employee of any other Investor, and represents the investment decision of such Additional Investor alone,
(b) no other Investor has acted as an agent of such Additional Investor in connection with the exchange hereunder and that no other Investor shall be acting as an agent of such Investor in
connection with monitoring its investment hereunder, (c) no representation or warranty is being made by the MDCP Co-Investors, the Company, the Group or any of their respective
Affiliates (collectively, the "MDCP Co-Investor Parties") or being relied upon by any Additional Investor in connection with the exchange
hereunder and the transactions contemplated hereby and the other agreements or documents being delivered by such Additional Investor hereunder, (d) forever releases, discharges and covenants
not to sue any of the MDCP Co-Investor Parties in any matter in connection with the exchange for Ordinary Shares hereunder and the transactions contemplated hereby and the other agreements
or documents being delivered by such Additional Investor hereunder, except for representations, warranties and covenants expressly made by such MDCP Co-Investor Party and set forth in this
Agreement and the other agreements and documents contemplated hereby to which such MDCP Co-Investor Party is a party, (e) other than costs and expenses expressly agreed to be paid
by the Company in writing, such 

Additional
Investor is solely responsible for all costs, expenses, taxes, duties, filing fees and charges arising out of the exchange for Ordinary Shares hereunder and any other transaction
contemplated hereby or by the agreements or documents delivered by such Additional Investor in connection with this Agreement, (f) the MDCP Co-Investor Parties have retained
Kirkland & Ellis LLP and Arthur Cox in connection with the transactions contemplated hereby and expect to retain Kirkland & Ellis LLP and Arthur Cox as legal counsel in connection with
the management and operation of the investment in the Company, (g) Kirkland & Ellis LLP and Arthur Cox are not representing and will not represent any Additional Investor in connection
with the transactions contemplated hereby or any dispute which may arise between any of the MDCP Co-Investor Parties, on the one hand, and any Additional Investor, on the other hand,
(h) such Additional Investor will, if it wishes counsel on the transactions contemplated hereby, retain at its own expense its own independent counsel, and (i) Kirkland & Ellis
LLP and Arthur Cox may represent the MDCP Co-Investor Parties in connection with any and all matters contemplated hereby (including, without limitation, any dispute or litigation between
any of the MDCP Co-Investor Parties, on the one hand, and any Additional Investor, on the other hand). 

        Section 7.    Restrictions on Transfer.    

        7A.    General.    Unless otherwise consented to by the MDCP Co-Investor Majority, no Investor may
directly or indirectly (including by means of a change of ownership or change of control of such Investor or any Person directly or indirectly controlling such Investor if such change is designed to
circumvent the provisions of this Agreement) sell, assign, transfer, exchange, mortgage, pledge, grant a security interest in, or otherwise dispose of or encumber (including by operation of law) all
or any part of such Investor's Ordinary Shares (a "Transfer"), except as provided in this paragraph 7A or permitted by paragraphs 7B or 7C and no
such Transfer shall relieve the transferor of its obligations hereunder. The restrictions set forth in this paragraph 7A shall not apply with respect to any Transfer by any Investor
(i) in the case of any Investor who is an individual, pursuant to applicable laws of descent and distribution or among such Investor's Family Group or (ii) in the case of an Investor
which is a company or partnership, among its Affiliates, and in the case of any MDCP Co-Investor, to its direct or indirect partners and investors or to other investment funds controlling,
controlled by or common control with such MDCP Co-Investor (collectively referred to herein as "Permitted Transferees");  provided that the restrictions
contained in this Section 7 shall continue to be applicable to the
transferred Ordinary Shares after any such Transfer; provided further that the transferees of such Ordinary Shares shall have executed and delivered to
the Board a Deed of Adherence in form and substance acceptable to the Company and the MDCP Co-Investor Majority (x) to be bound by the terms herein in the same manner and to the
same extent as the transferor thereof and (y) assuming the obligations of the transferor hereunder with respect to the Ordinary Shares so transferred. Without limiting the proviso and the
further proviso of the immediately foregoing sentence, (x) Permitted Transferees of DBCP Europe GP (Jersey) Limited shall include (i) Deutsche Bank AG, its Subsidiaries, holding
companies and other Subsidiaries of any such holding company ("DBAG Group"), (ii) DB Capital Partners (Europe) 2002 L.P. (or a similar named
entity), and/or any other partnership, fund or other investment entity established, managed, advised (including where a general partner of a partnership is advised) or sponsored by any member of the
DBAG Group as a co-investment scheme operated wholly or partially for the benefit of employees of any member of the DBAG Group ("DB
Partnership"), any principal or executive of the DBAG Group and every nominee or other trustee of any such person, partnership, fund, investment entity or (iii) the
general partner of such DB Partnership to hold on behalf of the DB Partnership, (y) Permitted Transferees of each of J.P. Morgan Partners Global Investors, L.P., J.P. Morgan Partners Investors
(Cayman), L.P., J.P. Morgan Partners Global Investors A, L.P., J.P. Morgan Partners Global Investors (Cayman) II, L.P and J.P. Morgan Partners (BHCA), L.P. shall include (i) JP Morgan Chase,
its Subsidiaries, holding companies and other Subsidiaries of such holding company (the "JPM Group"), (ii) any other partnership, fund or other
investment entity established, managed, advised (including where a general partner of a partnership is advised) or sponsored by any member of the JPM Group as a co-investment scheme
operated wholly or partially for the benefit of employees of any member of the JPM Group ("JPM Partnership"), any principal or executive of the JPM
Group and every 

nominee
or other trustee of any such person, partnership, fund, investment entity or (iii) the general partner of such JPM Partnership to hold on behalf of the JPM Partnership, and
(z) Permitted Transferees of each of Arthur Street Portfolio, L.P., Arthur Street Fund, L.P., Vesey Street Portfolio, L.P., Vesey Street Fund, L.P. and Passage Portfolio, L.P. shall include
(i) Merrill Lynch & Co., Inc., its Subsidiaries, holding companies and other Subsidiaries of any such holding company ("ML Group"),
(ii) any other partnership, fund or other investment entity established, managed, advised (including where a general partner of a partnership is advised) or sponsored by any member of the ML
Group as a co-investment scheme operated wholly or partially for the benefit of employees of any member of the ML Group ("ML Partnership"),
any principal or executive of the ML Group and every nominee or other trustee of any such person, partnership, fund, investment entity or (iii) the general partner of such ML Partnership to
hold on behalf of the ML Partnership. Notwithstanding the
foregoing, no party hereto shall avoid the provisions of this Agreement by making one or more Transfers to one or more Permitted Transferees and subsequently disposing of all or any portion of such
party's interest in any such Permitted Transferee. 

        7B.    Sale of the Company.    

        (i)    If
the Board and MDCP Co-Investor Majority approve a Sale of the Company (an "Approved Sale"), each Investor
shall vote for, consent to and raise no objections against such Approved Sale. If the Approved Sale is structured as a (a) merger or consolidation, each Investor shall waive any minority
rights, objection rights, appraisal rights or similar rights in connection with such merger or consolidation or (b) sale of Ordinary Shares, each Investor shall agree to Transfer all of its
Ordinary Shares and rights to acquire Ordinary Shares on the terms and conditions approved by the Board. Each Investor holding Ordinary Shares shall promptly take all necessary or desirable actions in
connection with the consummation of the Approved Sale as requested by the Board. 

        (ii)   The
obligations of the Investors holding Ordinary Shares with respect to the Approved Sale are subject to the satisfaction of the following conditions: (a) upon
the consummation of the Approved Sale, all of the holders of Ordinary Shares shall receive the same form and amount of consideration per Ordinary Share; and (b) if any Investors, as the case
may be, are given an option as to the form and amount of consideration to be received, in respect of their Ordinary Shares, each Investor shall be given the same option. 

        (iii)  Each
Investor Transferring Ordinary Shares pursuant to this paragraph 7B shall pay its pro rata share (based on the relative aggregate amount of consideration
received by each Investor pursuant to such Transfer of such Ordinary Shares) of the expenses incurred by the Company and the Investors in connection with such Transfer and shall be obligated to
transfer such Ordinary Shares on such terms, conditions, warranties, representations, covenants, undertakings, indemnities and other obligations that the Board specifies in connection with such
Transfer (other than any such obligations that relate specifically to a particular Investor such as indemnification with respect to representations and warranties given by a Investor regarding such
Investor's title to and ownership of Ordinary Shares, which such Investor shall be required to provide only with respect to itself and its Ordinary Shares);  provided that no Investor shall be obligated
in connection with such Transfer to agree to indemnify or hold harmless the transferees with respect to an
amount in excess of the net proceeds paid to such holder in connection with such Transfer; provided further that, without limiting the obligations of
any other Investor, no Investor shall be required to provide any indemnification (other than indemnification with respect to representations and warranties given by such Investor regarding such
Investor's title to and ownership of Ordinary Shares) that would violate any provision of such Investor's constitutive documents as in effect on the date of this Agreement. 

        7C.    Tag-Along Rights.    

        (i)    At
least 30 days prior to any Transfer (other than an Exempted Transfer) by any MDCP Co-Investor or its Permitted Transferees of Ordinary Shares, such
MDCP Co-Investor 

or
the Company shall deliver a written notice (the "Sale Notice") to each other Investor (collectively, the "Other
Investors") specifying in reasonable detail the identity of the prospective transferee(s), the number of Ordinary Shares to be transferred and the terms and conditions of the
proposed Transfer. 

        (ii)   Upon
receipt of the Sale Notice, the Other Investors may elect to participate in the contemplated Transfer by delivering written notice to the Board within
15 days after delivery of the Sale Notice. Such participation shall be based on the pro rata share represented by the Ordinary Shares owned by each Investor participating in such Transfer
relative to the aggregate number of all Ordinary Shares and Class D Convertible Shares owned by Persons participating in such Transfer. If the Other Investors have not elected to participate in
the contemplated Transfer (through notice to such effect or expiration of the 15-day period after delivery of the Sale Notice), then the MDCP Co-Investor proposing to make such
Transfer and its Permitted Transferee may Transfer the Ordinary Shares specified in the Sale Notice at a price and on terms no more favorable to the transferee(s) thereof than specified in the Sale
Notice during the 90-day period immediately following the date of the delivery of the Sale Notice. The Ordinary Shares of the MDCP Co-Investor and its Permitted Transferees not
Transferred within such 90-day period shall be subject to the provisions of this paragraph 7C upon subsequent Transfer thereof. 

        (iii)  The
MDCP Co-Investor and any Permitted Transferee proposing to Transfer Ordinary Shares shall use reasonable best efforts to obtain the agreement of the
prospective transferee(s) to the participation of the Other Investors who have elected to participate in any contemplated Transfer, and shall not Transfer any of its Ordinary Shares to any prospective
transferee if such prospective transferee(s) declines to allow the participation of the Other Investors to the extent permitted by this paragraph 7C. Each Investor transferring Ordinary Shares
pursuant to this paragraph 7C shall pay its pro rata share (determined on a pro rata basis, based upon the number of Ordinary Shares transferred) of the expenses incurred by the Investors and
the Company in connection with such Transfer and shall be obligated to join in any terms, conditions, warranties, representations, covenants, undertakings, indemnities and other obligations that the
MDCP Co-Investor, any of its Permitted Transferees, the Board or the Company agrees to provide in connection with such Transfer (other than any such obligations that relate specifically to
a particular Investor such as indemnification with respect to representations and warranties given by an Investor regarding such shareholder's title to and ownership of Ordinary Shares, which such
Investor shall be required to provide only with respect to itself and its Ordinary Shares); provided that no Investor shall be obligated in connection
with such Transfer to agree to indemnify or hold harmless the transferees with respect to an amount in excess of the net proceeds paid to such Investor in connection with such Transfer;  provided further
that, without limiting the obligations of any other Investor, no Investor shall be required to provide any indemnification (other than
indemnification with respect to representations and warranties given by such Investor regarding such Investor's title to and ownership of Ordinary Shares) that would violate any provision of such
Investor's constitutive documents as in effect on the date of this Agreement. 

        Section 8.    Voting Agreement.    So long as the MDCP Co-Investors and their respective Permitted
Transferees collectively hold a majority of the Ordinary Shares, each Investor shall vote all of its Equity Securities and take all other necessary or desirable actions (in such holder's capacity as a
shareholder of the Company) as are requested by the MDCP Co-Investor Majority in order to cause the representatives to be elected as members of the Board as set forth in the Corporate
Governance Agreement and as otherwise directed by the MDCP Co-Investor Majority. In addition, each Investor shall not vote its Equity Securities in connection with the removal of any of
any designee of the MDCP Co-Investor Majority or any other Board member as a director unless and until the MDCP Co-Investor Majority directs such Investor how to vote on such
removal. In addition, each Investor shall at all such times vote his or her Equity Securities on all matters presented to the Company's shareholders as directed by the MDCP Co-Investor
Majority as long as such vote is not materially adversely 

discriminatory
to such Investor in a manner different from the MDCP Co-Investor Majority. The provisions of this Section 8 shall terminate as of the effective date of the Company's
initial Listing or upon consummation of a Sale of the Company. 

        Section 9.    Transfers; Future Sales.    Prior to any Investor Transferring any Ordinary Shares to any Person
(other than pursuant to a Listing or to a MDCP Co-Investor or its Permitted Transferees) or any Equity Securities or Equity Equivalents to any Person, such Investor shall cause the
prospective transferee to be bound by this Agreement and to execute and deliver to the Company and the other Investors a Deed of Adherence to this Agreement in form and substance satisfactory to the
MDCP Co-Investors and the Company. Transferees of Ordinary Shares held by Additional Investors shall be deemed to have the rights and obligations of Additional Investors with respect to
such Ordinary Shares and transferees of Ordinary Shares held by any MDCP Co-Investor shall be deemed to have the rights and obligations of MDCP Co-Investors with respect to
such Ordinary Shares; provided that notwithstanding the foregoing Ordinary Shares acquired by a MDCP Co-Investor from an Additional Investor
shall be deemed to have the rights and obligations of Ordinary Shares held by a MDCP Co-Investor. 

        Section 10.    Definitions.    For the purposes of this Agreement, the following terms have the meanings set
forth below: 

        "Affiliate" of any particular person or entity means any other person or entity controlling, controlled by or under common control with
such particular person or entity. 

        "Class D Convertible Shares" means Class D Convertible Shares of the Company, nominal value €0.001 per
share. 

        "Corporate Governance Agreement" means that certain Corporate Governance Agreement, dated as of February 6, 2004, by and among the
Company, MDCP IV and the other parties signatory thereto, as amended, modified, supplemented or waived from time to time. 

        "Equity Equivalents" means any securities convertible into or exchangeable for any Equity Securities, including without limitation,
warrants, options and other rights to acquire Equity Securities. 

        "Equity Securities" means any shares, share derivatives, share appreciation rights or other rights or instruments containing
equity-like features or otherwise based on changes in the enterprise value of the issuer thereof or its Affiliates (other than ordinary course cash bonus payments) and any rights to
acquire any such right or instrument. 

        "Excluded Issuances" means the issuance of (i) any Ordinary Shares after the date hereof for management incentive and/or
compensation purposes, (ii) any Ordinary Shares (other than issuances to the MDCP Co-Investors in their capacity as equity holders of the Company) issued as consideration for an
acquisition or joint venture transaction, (iii) any Ordinary Shares issued as an "equity kicker" in respect of indebtedness for borrowed money or any preferred Equity Securities,
(iv) any Ordinary Shares issued upon conversion of any Equity Securities or Equity Equivalents, (v) any options, warrants or rights to acquire, or shares convertible into, Ordinary
Shares listed in clauses (i) through (iv), and (vi) Ordinary Shares issued in connection with or pursuant to a Public Sale. 

        "Exempted Transfer" means a Transfer (i) to one or more Affiliates of a MDCP Co-Investor or its Permitted Transferees,
(ii) to any members, partners, shareholders, officers or directors of a MDCP Co-Investor or entity controlling, controlled by or under common control with a MDCP
Co-Investor or among the Family Group of any such Person, (iii) up to 25% of the aggregate Ordinary Shares held by the MDCP Co-Investors and their Permitted Transferees
as of the Settlement Date plus the aggregate Ordinary Shares purchased by the MDCP Co-Investors and their Permitted Transferees after the Settlement Date, (iv) to any Person who
becomes an Additional Investor hereunder on or prior to the Settlement Date or (v) in a Public Sale. 

        "Family Group" means, with respect to any Investor, such Investor's spouse and descendants (whether natural or adopted) and any trust
solely for the benefit of such Investor and/or such Investor's spouse, descendants, siblings and/or siblings' descendants. 

        "5% Owner" means any Person that owns 5% or more of the Company's Ordinary Shares on a fully-diluted basis. 

        "Independent Third Party" means any Person who, immediately prior to the contemplated transaction, is not a 5% Owner, who is not
controlling, controlled by or under common control with any 5% Owner and who is not the spouse or descendent (by birth or adoption) of any 5% Owner. 

        "Listing" means the admission of all or any part of the Ordinary Shares to the Official List of The Irish Stock Exchange Limited or the
Official List of the UK Listing Authority, and to trading on the market for listed securities of the London Stock Exchange or to trading on the Alternative Investment Market or the taking effect of
any granting of permission to deal in the same on any recognized investment exchange (as that term is used in the Financial Services Act 1986) or the registration of all or any of the Ordinary Shares
(or equivalent securities of any Subsidiary or American Depository Receipts with respect to any of the forgoing) on Form F-1, F-2 or F-3 (or any similar
long-form or short-form registrations) pursuant to the United States Securities Act of 1933 (as amended) or any similar US federal law, or any similar listing or registration
by the Company of the Ordinary Shares on the public stock exchange or securities market in any other jurisdiction. 

        "MDCP Co-Investor Majority" means the holders of a majority of the Ordinary Shares held by all MDCP Co-Investors. 

        "MDCP Co-Investors" means, collectively, MDCP IV Global Investments LP, MDCP III Global Investments LP, MDSE III Global
Investments LP and any Affiliate of the foregoing that owns or holds Ordinary Shares as of the date of determination and "MDCP Co-Investor" means any of the MDCP Co-Investors. 

        "MEIA" means the Company's Management Equity Incentive Agreement, dated as of February 6, 2004, by and among the Company and
certain of its executives, as such agreement may be amended, restated, supplemented or waived from time to time. 

        "MIP" means the Company's 2004 Management Equity Plan, approved by the Company on February 6, 2004, as amended, restated,
supplemented or waived from time to time. 

        "Ordinary Shares" means ordinary shares of the Company, nominal value €0.001 per share. 

        "Person" means an individual, a partnership, a limited liability company an unlimited liability company, a company limited by guarantee, a
corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. 

        "Public Sale" means (x) any sale after a Listing in any European Union member state or (y) in the case of a Listing in the
United States, any sale pursuant to a registered public offering under the Securities Act or any sale to the public pursuant to Rule 144 promulgated under the Securities Act effected through a
broker, dealer or market maker. 

        "Registration Agreement" means that certain Registration Rights Agreement, dated as of February 6, 2004, by and among the Company,
MDCP IV and the other parties signatory thereto, as amended, modified, supplemented or waived from time to time. 

        "Sale of the Company" means the sale of the Company to an Independent Third Party or affiliated group of Independent Third Parties
pursuant to which such party or parties acquire (i) capital stock of the Company possessing the voting power to elect a majority of the Company's board of directors (whether by merger,
consolidation or sale or transfer of the Company's capital stock) or (ii) all or substantially all of the Company's assets determined on a consolidated basis. 

        "Securities Act" means the Securities Act of 1933, as amended. 

        "Subsidiary" means any Company of which the securities having a majority of the ordinary voting power in electing the board of directors
are, at the time as of which any determination is being made, owned by the Company either directly or through one or more Subsidiaries. 

        Section 11.    Miscellaneous.    

        11A.    Complete Agreement.    This Agreement and the agreements contemplated hereby embody the complete agreement and
understanding among the parties hereto with respect to the purchase of Ordinary Shares and supersedes and preempts any prior understandings, agreements or representations by or among the parties,
whether written or oral, which may have related to the subject matter hereof in any way. Without limiting the generality of the immediately foregoing sentence, except as expressly set forth in this
Agreement, none of the Company nor any MDCP Co-Investor has made or shall be deemed to have made any representation or warranty to any Additional Investor
regarding the purchase and sale of Ordinary Shares hereunder and the transactions contemplated by this Agreement and the agreements contemplated hereby. Notwithstanding the foregoing, nothing herein
shall be deemed to amend, supersede or preempt any agreement of an Investor made in any Acceptance Form included with that certain Exchange Offer information memorandum dated on or about
January 20, 2004, including, without limitation, the power of attorney executed in connection therewith, in any side letter executed (or, in accordance with this Section 11, deemed
executed) by the Company, or in any letter agreement between the Company and an Investor or Affiliate of an Investor regarding payment of fees, expenses and interest in the event that the share
capital reduction is not consummated. 

        11B.    Remedies.    Each holder of Ordinary Shares shall have all rights and remedies set forth in this Agreement and
the Articles of Association and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any
law. Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason
of any breach of any provision of this Agreement and to exercise all other rights granted by law. 

        11C.    Consent to Amendments.    Except as otherwise expressly provided herein, the provisions of this Agreement may
be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the MDCP
Co-Investor Majority or, in the event that no MDCP Co-Investor holds Ordinary Shares, the holders of a majority of the Ordinary Shares then held by Investors and their
Permitted Transferees; provided that if any such amendment, modification or waiver would materially adversely affect any Investor relative to the MDCP Co-Investor Majority, such amendment,
modification or waiver shall be effective against such Investor only with the written consent of such Investor or the holders of a majority of Ordinary Shares held by all holders so adversely
affected. No other course of dealing between the Company and any Investor or any delay in exercising any rights hereunder, under any agreement contemplated hereby or under the Articles of Association
shall operate as a waiver of any rights of any such holders. Each Additional Investor agrees and acknowledges that the Company may issue Ordinary Shares hereunder after such Investor's Exchange Date,
that the Person acquiring such Ordinary Shares may become a party hereto as an Additional Investor and that the Schedule of Investors and  Schedule of Additional
Investors may be updated by the Company to reflect any such issuance, in each case without the consent of any Additional Investor
hereunder. 

        11D.    Successors and Assigns.    Except as otherwise expressly provided herein, all covenants and agreements
contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not.
In addition, and whether or not any express assignment has been made, the provisions of this Agreement which are for the Investors' benefit as purchasers or holders of Ordinary Shares are, except as
otherwise set forth herein, also for the benefit of, and enforceable by, any subsequent holder of such shares. The rights and obligations of any Investor under this Agreement and the agreements
contemplated hereby may be assigned by such Investor at any time only with the prior written consent of such Investor. 

        11E.    Severability.    Whenever possible, each provision of this Agreement shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent
of such prohibition or invalidity, without invalidating the remainder of this Agreement. 

        11F.    Counterparts.    This Agreement may be executed simultaneously in two or more counterparts, any one of which
need not contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same Agreement. 

        11G.    Descriptive Headings; Interpretation.    The descriptive headings of this Agreement are inserted for
convenience only and do not constitute a Section of this Agreement. The use of the word "including" in this Agreement shall be by way of example rather than by limitation. 

        11H.    Governing Law.    The Agreement and the exhibits and schedules hereto shall be governed by and construed in
accordance with the laws of the State of Illinois without reference to its conflict of laws rules and the parties hereby submit to the non-exclusive jurisdiction of state and federal
courts located in the State of Illinois. 

        11I.    Notices.    All notices, demands or other communications to be given or delivered under or by reason of the
provisions of this Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient, one day after being sent to the recipient by reputable express
courier service by overnight mail (charges prepaid) or by facsimile. Such notices, demands and other communications shall be sent to the Investors and to the Company at the address indicated below: 

If to the Company:

c/o
Jefferson Smurfit Group Limited

Headquarters

Beech Hill

Clonsekagh

Dublin 4

Facsimile: 353-1-283-7113 

with copies to:

William
Fry

Solicitors

Fitzwilton House

Wilton Place

Dublin 2

Attention: Owen O'Connell

Facsimile: +353-1-618-0618

and
to the MDCP Co-Investors and Kirkland & Ellis LLP (at the addresses set forth below) 

If to the MDCP Co-Investors:

c/o
Madison Dearborn Partners, LLC

Three First National Plaza,

Suite 3800

Chicago, Illinois 60602

USA

Attention: Samuel M. Mencoff

Facsimile: 312-895-1001 

with a copy to:

Kirkland &
Ellis LLP

200 East Randolph Drive

Chicago, IL 60601

USA Attention: William S. Kirsch, P.C.

Facsimile: (312) 861-2200 

If to an Additional Investor:

To
the address set forth for such Additional Investor

on the Schedule of Additional Investors attached hereto 

or
to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. 

        11J.    No Strict Construction.    The parties hereto have participated jointly in the negotiation and drafting of
this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of
proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. 

        11K.    Side Letters.    Notwithstanding anything herein to the contrary, each of the Company and each Investor agree
that, in connection with such Investor's investment in MDCP Acquisitions Limited (formerly MDCP Acquisitions plc), MDCP Acquisitions Limited entered into certain side letter agreements with
certain of the Investors and to the extent that any obligations under any such side letter have not been fully performed by MDCP Acquisitions Limited or any of its Subsidiaries prior to the date
hereof, the obligations of MDCP Acquisitions Limited under such side letter shall from and after the Exchange Date become obligations of the Company as though the Company were originally party
thereto. Furthermore, any agreement of any Investor evidenced in any side letter (including to the extent such had the effect of amending rights or obligations of any such Investor or the transferor
of any Ordinary Shares held by such Investor) shall remain in full force and effect and binding upon each such Investor. 

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first written above. 

	 	 	JSG PACKAGING LIMITED
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Its:	 	 
	 	 	 	 	

	

 	
 	

MDCP IV GLOBAL INVESTMENTS LP
	

 	
 	

By:	
 	

MDP IV Global GP, LP
	 	 	Its:	 	General Partner
	

 	
 	

By:	
 	

MDP Global Investors Limited
	 	 	Its:	 	General Partner
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Its:	 	 
	 	 	 	 	

	

 	
 	

MDCP III GLOBAL INVESTMENTS LP
	

 	
 	

By:	
 	

MDP III Global GP, LP
	 	 	Its:	 	General Partner
	

 	
 	

By:	
 	

MDP Global Investors Limited
	 	 	Its:	 	General Partner
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Its:	 	 
	 	 	 	 	

	

 	
 	

MDSE III GLOBAL INVESTMENTS LP
	

 	
 	

By:	
 	

MDP III Global GP, LP
	 	 	Its:	 	General Partner
	

 	
 	

By:	
 	

MDP Global Investors Limited
	 	 	Its:	 	General Partner
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	Its:	 	 
	 	 	 	 	

[Signature Page to Subscription and Shareholders Agreement]

SCHEDULE OF INVESTORS

AS OF FEBRUARY 6, 2004  

	Name of Investor
 
	 	Number of

JSG Shares
	 	Number of

Ordinary Shares

	MDCP IV Global Investments, L.P.	 	39,020,270	 	39,020,270
	MDCP III Global Investments, L.P.	 	7,495,357	 	7,495,357
	MDSE III Global Investments, L.P.	 	166,429	 	166,429
	Mid-Ocean Europe GP (Jersey) Limited	 	7,500,000	 	7,500,000
	J.P. Morgan Partners (BHCA), L.P.	 	2,757,089	 	2,757,089
	J.P. Morgan Partners Global Investors, L.P.	 	436,894	 	436,894
	J.P. Morgan Partners Global Investors A, L.P.	 	59,558	 	59,558
	J.P. Morgan Partners Global Investors (Cayman), L.P.	 	221,747	 	221,747
	J.P. Morgan Partners Global Investors (Cayman) II, L.P.	 	24,712	 	24,712
	Arthur Street Portfolio, L.P.	 	113,400	 	113,400
	Arthur Street Fund, L.P.	 	201,450	 	201,450
	Vesey Street Portfolio, L.P.	 	572,550	 	572,550
	Vesey Street Fund, L.P.	 	441,750	 	441,750
	Passage Portfolio, L.P.	 	170,850	 	170,850
	Techline Investment Ltd.	 	3,470,845	 	3,470,845
	Teachers Insurance and Annuity Association of America	 	1,983,339	 	1,983,339
	BVCF IV, L.P.	 	247,918	 	247,918
	TCW/Crescent Mezzanine Partners III, L.P.	 	423,531	 	423,531
	TCW/Crescent Mezzanine Trust	 	65,982	 	65,982
	TCW Crescent Mezzanine Partners III Netherlands, L.P.	 	17,304	 	17,304
	Stanley Shuman	 	49,584	 	49,584
	Maxce LLC	 	99,167	 	99,167
	Eran Ashany	 	14,876	 	14,876
	Walter O'Hara, Jr.	 	9,918	 	9,918
	Robert Dean	 	2,480	 	2,480
	Special Co-Invest I	 	50,000	 	50,000
	Schwerin Company, L.L.C.	 	25,000	 	25,000
	Paul J. Magnell	 	25,000	 	25,000
	Northwestern University	 	10,000	 	10,000
	Randolph Street Partners V	 	125,000	 	125,000
	 	 	
	 	

	 	TOTAL	 	65,802,000	 	65,802,000

SCHEDULE OFADDITIONAL INVESTORS

AS OF FEBRUARY 6, 2004  

Mid-Ocean
Europe GP (Jersey) Limited

Mid-Ocean Partners

3rd Floor

1 Chester Street

London SW1X 7HP

Attention: Hugh Briggs 

J.P.
Morgan Partners Global Investors, L.P.

J.P. Morgan Partners

1221 Avenue of the Americas, 39th Floor

New York, NY 10020

Attention: Robert Ruggiero 

J.P.
Morgan Partners Investors (Cayman), L.P.

J.P. Morgan Partners

1221 Avenue of the Americas, 39th Floor

New York, NY 10020

Attention: Robert Ruggiero 

J.P.
Morgan Partners Global Investors A, L.P.

J.P. Morgan Partners

1221 Avenue of the Americas, 39th Floor

New York, NY 10020

Attention: Robert Ruggiero 

J.P.
Morgan Partners Global Investors

    (Cayman) II, L.P.

J.P. Morgan Partners

1221 Avenue of the Americas, 39th Floor

New York, NY 10020

Attention: Robert Ruggiero 

J.P.
Morgan Partners (BHCA), L.P.

J.P. Morgan Partners

1221 Avenue of the Americas, 39th Floor

New York, NY 10020

Attention: Robert Ruggiero 

Arthur
Street Portfolio, L.P.

Merrill Lynch Private Equity Partners

800 Scudders Mill Road

Plainsboro, NJ 08536

Attention: Mike Cerminaro 

Arthur
Street Fund, L.P.

Merrill Lynch Private Equity Partners

800 Scudders Mill Road

Plainsboro, NJ 08536

Attention: Mike Cerminaro 

Vesey
Street Portfolio, L.P.

Merrill Lynch Private Equity Partners

800 Scudders Mill Road

Plainsboro, NJ 08536

Attention: Mike Cerminaro 

Vesey
Street Fund, L.P.

Merrill Lynch Private Equity Partners

800 Scudders Mill Road

Plainsboro, NJ 08536

Attention: Mike Cerminaro 

Passage
Portfolio, L.P.

Merrill Lynch Private Equity Partners

800 Scudders Mill Road

Plainsboro, NJ 08536

Attention: Mike Cerminaro 

Northwestern
University

Investment Office

633 Clark Street, Crown 1-209

Evanston, IL 60208

Attention: Du H. Chai 

Techline
Investment Ltd.

GIC Special Investments Pte Ltd

156 West 56th Street

Suite 190

New York, NY 10019

Attention: David L. Chiang 

Teachers
Insurance and Annuity Association of America

TIAA-CREF

730 Third Avenue

New York, NY 10017

Attention: Holly D. Holtz 

BVCF IV,
L.P.

Adams Street Partners

One North Wacker

Suite 2200

Chicago, IL 60606-2807

Attention: David S. Timson 

TCW/Crescent
Mezzanine Trust

TCW/Crescent Mezzanine, LLC

200 Crescent Court

Suite 1600

Dallas, TX 75201

Attention: Tim Costello 

TCW/Crescent
Mezzanine Partners III, L.P.

TCW/Crescent Mezzanine, LLC

200 Crescent Court

Suite 1600

Dallas, TX 75201

Attention: Tim Costello 

TCW
Crescent Mezzanine Partners III

Netherlands, L.P

TCW/Crescent Mezzanine, LLC

200 Crescent Court

Suite 1600

Dallas, TX 75201

Attention: Tim Costello 

Randolph
Street Partners V

Kirkland & Ellis LLP

200 East Randolph Drive

Chicago, IL 60601

Attention: William Kirsch 

Stanley
Shuman

Allen & Company

711 5th Avenue

New York, NY 10022 

Macxe
LLC

Allen & Company

711 5th Avenue

New York, NY 10022 

Eran
Ashany

Allen & Company

711 5th Avenue

New York, NY 10022 

Walter
O'Hara, Jr.

Allen & Company

711 5th Avenue

New York, NY 10022 

Robert
Dean

Allen & Company

711 5th Avenue

New York, NY 10022 

Schwerin
Company, L.L.C.

Michael Schwerin

President

One Bayview Avenue

Oyster Bay, New York 11771 

Paul
Magnell

CEO

Bay State Paper Company

892 River Street

Hyde Park, MA 02136 

Special
Co-Invest I

Madison Dearborn Partners, LLC

Three First National Plaza

Suite 3800

Chicago, Illinois 60602

Attention: David Mosher 

QuickLinks

Exhibit 10.5

EXCHANGE AND SHAREHOLDERS AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.6    
    

Jefferson Smurfit Group Limited  

Beech Hill, Clonskeagh,

Dublin 4, Ireland. 

Tel
(+353 1) 202 7000

Fax (+353 1) 269 4481 

31 October 2003 

PERSONAL
AND CONFIDENTIAL 

Dr. Michael
W.J. Smurfit

Le Florestan

35 Blvd. du Larvotto

Monaco 

Dear
Dr. Smurfit: 

On
behalf of Jefferson Smurfit Group Limited ("JSG"), we are pleased to offer you, with effect from 1 January 2003, the following terms and conditions of employment by JSG. 

	1.
	You
will be the Chairman of the Board of Directors of JSG (the "Board") on the terms and conditions set out in this letter. As Chairman, you will be responsible and report to the
Board.

	2.
	Your
role of Chairman will include the responsibility of chairing and conducting the meetings of the Board and such other duties and responsibilities as may be agreed between JSG and
yourself from time to time.

	3.
	Your
aggregate compensation will be €300,000.00 per annum (the "Compensation"). The salary component of the Compensation will be paid in equal installments in
accordance with JSG's payroll practices. All remuneration and amounts payable to you pursuant to this paragraph 3 or otherwise shall be subject to such tax and other statutory deductions as are
required to be deducted at source and remitted to the appropriate revenue authorities. You will not be entitled to receive any additional compensation or any expense reimbursement from JSG.

	4.
	Subject
to earlier termination by JSG or you, you will serve as Chairman until November 1, 2008. If your employment is terminated by JSG prior to that date, either with or
without cause, you will be entitled to receive as severance an amount equal to one year's Compensation. Such severance shall be payable to you within thirty days of your termination of employment. As
a pre-condition to your receipt of any such severance payments and as a material term of this agreement, you agree that in the event of such termination you will execute a mutually
acceptable and complete release in favor of each of the Group Companies (including, without limitation, a full and final settlement, discharge and waiver of all rights under law (including but not
limited to statutory, contractual and other common law rights) with respect to your employment and/or the termination of your employment and/or such payment upon any termination in which you are
entitled to such severance benefits). The rights under this paragraph shall be in replacement of, rather than in addition to, any rights that you may have under law (including, without limitation,
payment in lieu of notice).

	5.
	When
used herein, "Group Companies" means JSG and each of its subsidiaries and Associated Companies and "Group Company" means any such company and "Associated Company" means any
company having an Equity Share Capital (as defined in Section 155 of the Companies Act 1963) of which not less than 20% in nominal value is beneficially owned by any Group Company.

	6.
	You
agree that so long as you serve on the board of any Group Company (the "Restricted Period") you shall not: (i) within any area of the world where any Group Company conducts
a material portion of its business (the "Restricted Area") or any part thereof, carry on either directly or indirectly, on your own behalf or on behalf of any other person, firm, company or entity,
any 

material
business of the same or similar kind to that in which any Group Company is engaged, (ii) induce or attempt to induce any employee of any Group Company to leave the employ of the Group
Companies, or in any way interfere with the relationship between any Group Company and any employee thereof and or (iii) call on, solicit the custom or business of or service any customer,
supplier, licensee, licensor or other business relation of any Group Company in order to induce or attempt to induce such person or entity to cease doing or reduce the amount of business with any
Group Company, or in any way interfere with the relationship between any such customer, supplier, licensee or business relation and any Group Company (including but not limited to making any negative
statements or communications about any Group Company, or any employee, director or stockholder thereof). 

	7.
	You
agree that all trade secrets, confidential operations, processes or dealings, or any information concerning the organization, business, finances, transactions and affairs, other
than information that becomes publicly available other than through breach of this provision by you, shall be kept confidential both during the term of this letter agreement and thereafter. All notes,
memoranda, reports and information compiled by you during your employment (in whatever form compiled) regarding the business, affairs and operations of the Group Companies shall be and at all times
remain the property of the Group Companies.

	8.
	Effective
as of the date of this letter agreement, you agree that all indemnification agreements or provisions currently in effect between you and any of the Group Companies with
respect to existing litigation arising in Spain shall be amended to require JSG's consent prior to settlement in excess of €47.0 million in the aggregate. Subject to the
amendment set forth in the immediately foregoing sentence, JSG will cause the Group Companies to honor the indemnification obligations with respect to the Spanish litigation to you as such agreements
exist as of the date of this letter.

	9.
	We
agree that the Chairman's Dinner in Dublin will continue as an annual event, at the expense of JSG and its Subsidiaries, and will be hosted by you in your capacity as Chairman of
JSG and its subsidiaries.

	10.
	Upon
execution of this letter agreement by each party hereto, this letter agreement shall be binding and enforceable upon each party hereto and shall amend and supersede any other
agreement(s) with JSG and/or any of its subsidiaries regarding the subject matter hereof to which you are a party prior to the date hereof. Provided, however, that nothing in this letter agreement
shall prevent you from entering into and exercising and performing all your rights and responsibilities under any consultancy or employment agreements with any other Member of the Group, any such
agreement to be effective in accordance with its terms.

	11.
	The
Unfair Dismissals Act 1977 -2001 will not apply to a termination consisting only of the expiration of the term of your employment without it being renewed. 

	12.
	This
letter agreement may be executed in multiple counterparts (including by facsimile), each of which shall constitute one and the same original. This letter agreement shall be
construed in accordance with the internal laws of Ireland. 

	 	JEFFERSON SMURFIT GROUP LIMITED
	

 	

By:	
 	

    
	
 	

 
	

 	

Its:	
 	

    
	
 	

 
	

 	

Acknowledged and Accepted:
	

 	

DR. MICHAEL W.J. SMURFIT
	

 	

    
	
 	

 
	

 	

Date:	
 	

    
	
 	

 

QuickLinks

Exhibit 10.6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]